l19tnf
mAbexperimentalADC
Clinical trial activity
14 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
12
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT01253837)
Timeline
Indications
Studied for
- Basal Cell Carcinoma · Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Leiomyosarcoma · Phase 2
- Melanoma · Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Sarcoma · Phase 1
- Sarcoma, Kaposi · Phase 2
- Skin Neoplasms · Phase 2
Mechanism of action
- FibronectinBINDING AGENT
FN1 binding agent
Immunocytokine. Immunostimulant.
Directed against the extra-domain B (ED-B) of fibronectin (L19).
- FibronectinINHIBITOR
FN1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- TNF
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109589 ↗
Also known as
- l19tnf
- l19tnfa
- l19tnf-alpha
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07120984 | Phase 2 | Jan 30, 2026 | Philogen S.p.A. |
| NCT07228442 | Phase 2 | Dec 31, 2025 | Philogen S.p.A. |
| NCT07227870 | Phase 2 | Dec 31, 2025 | Philogen S.p.A. |
| NCT06336291 | Phase 2 | Jun 30, 2024 | Philogen S.p.A. |
| NCT05329792 | Phase 2 | Jul 1, 2022 | Philogen S.p.A. |
| NCT04573192 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2020 | Philogen S.p.A. |
| NCT04362722 | Phase 2 | Jun 1, 2020 | Cantonal Hospital of St. Gallen, Philogen S.p.A. |
| NCT04032964 | Phase 1 | Jul 31, 2019 | Philogen S.p.A. |
| NCT03779230 | Phase 1/Phase 2 (Phase 2) | May 31, 2019 | Philogen S.p.A., University of Zurich |
| NCT03420014 | Phase 2 | Jun 30, 2018 | Mayo Clinic, Philogen S.p.A. |
| NCT02938299 | Phase 3 | Jul 1, 2016 | Philogen S.p.A., University of Milan, University of Tuebingen |
| NCT02076620 | Phase 1 | Jan 1, 2013 | Philogen S.p.A., University of Milan |
| NCT02076633 | Phase 2 | Dec 1, 2012 | Philogen S.p.A., University of Milan |
| NCT01253837 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2007 | Eudax S.r.l., InnoPharma, Philogen S.p.A., University of Milan |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Philogen S.p.A. | For profit | 14 | 14 | 3 | 2007 |
| University of Milan | Academic/Hospital | 4 | 0 | 3 | 2007 |
| Cantonal Hospital of St. Gallen | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Eudax S.r.l. | For profit | 1 | 0 | 1 | 2007 |
| InnoPharma | For profit | 1 | 0 | 1 | 2007 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Tuebingen | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Zurich | Academic/Hospital | 1 | 0 | 1 | 2019 |
8 organizations
Page 1 / 1